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THE IMPACT OF SUBTHERAPEUTIC INITIAL DOSING ON ADHERENCE
TO ANTI-DEPRESSANTS IN THE TREATMENT OF DEPRESSION AND/OR
ANXIETY
Able S1, Bledsoe S1, Gelwicks SC2, Watson PR1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Physician decisions regarding initial anti-depressant dosing levels may
impact treatment outcomes. This study examined initial dosing levels and their associa-
tions with adherence among currently available selective serotonin and serotonin-
norepinephrine reuptake inhibitors (SSRIs and SNRIs). METHODS: A total of 
115,284 patients initiating treatment on an SSRI or SNRI during 2005 were selected
for analysis from a large managed-care claims database. Patients were assigned to a
drug cohort on the basis of their most recent prescription for one of the studied medi-
cations. The study included only patients with one or more ICD-9 coded diagnoses
for depression or anxiety within / 3 months of initiation of treatment with their
index drug, an initial 30 days supply of the index medication, and continuous eligibil-
ity of at least 6 months prior and 12 months following treatment initiation. Subthera-
peutic dosing levels of each studied medication were determined on the basis of label 
information. Outcome measures included early discontinuation (no second prescrip-
tion following initiation) and days on therapy with the index medication. All reported
differences were signiﬁ cant at the 0.01 level. RESULTS: A total of 13.6% of all study
patients initiated antidepressant treatment at a subtherapeutic dose. The share of 
patients initiating treatment at subtherapeutic levels varied substantially across medi-
cations: paroxetine, most frequently (30.1%) and escitalopram, least frequently
(2.7%). Across all studied medications, subtherapeutic initial dosing was associated 
with higher levels of early discontinuation (29.9%) and fewer average days on therapy 
(164.1) than initial dosing at therapeutic doses or higher (24.3% and 176.8 days,
respectively). These associations were directionally consistent across all studied medi-
cations. CONCLUSIONS: Initial dosing of antidepressants at subtherapeutic levels 
was associated with more frequent early discontinuation and fewer average days on 
treatment. Prescribers should be cognizant of the potential impact of initial dosing 
decisions on subsequent adherence to therapy.
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PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS
FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN ADULTS
Xiao X1, Damaraju C2, Durkin M2
1XYX Consulting Service Inc, Paoli, PA, USA, 2Ortho-McNeil Janssen Scientiﬁ c Affairs, LLC, 
Titusville, NJ, USA
OBJECTIVES: To examine patterns of augmentation of extended-release (ER) stimu-
lant regimens with immediate-release (IR) stimulants in an adult population, identify 
the factors associated with these patterns, and quantify those factors’ effects on likeli-
hood of augmentation. METHODS: Patients 18 years of age or older with prescription
claims for at least a 90-day supply from June 2005 to May 2006 for 1 of the following 
ER stimulants indicated for attention-deﬁ cit/hyperactivity disorder (ADHD)—ER dex-
methylphenidate (DEX-XR), ER mixed amphetamine salts (MAS-XR), or osmotic-
release oral system methylphenidate (OROS MPH)—and no ADHD medication use 
in the prior 180 days were selected from a large managed care database. Descriptive
statistics were reported for age, gender, health plan type, region, physician specialty, 
dose level, selected comorbidities, and stimulant cost by augmentation status and by 
ER stimulant. Chi-square tests were performed to assess differences in categorical
variables, and Student t tests were used to detect differences for mean age. A logistic
regression model for predicting positive augmentation status was formulated using
backward stepwise regression to evaluate the inclusion of potential explanatory vari-
ables. RESULTS: Of the 3234 adult patients eligible, 13.8% had IR augmentation 
with a mean incremental IR drug cost of $15.91 per month. Signiﬁ cant covariates for
the logistic model were health plan type (P  0.0022), bipolar disorder diagnosis (P 
0.0269), ER product (P  0.0001), and dose level (P  0.0345). Likelihood of aug-
mentation was higher with plan type “Other” i.e., not HMO, PPO, or POS), a diag-
nosis of bipolar disorder, use of DEX-XR or MAS-XR, and dose level of “medium.”
CONCLUSIONS: While this observational study quantiﬁ ed important aspects of the
augmentation of ER stimulants with IR stimulants from a claims data perspective,
more research is needed to identify the reasons for augmentation in adults with ADHD 
(e.g., duration of effect, titration) and to examine patterns of medication taking 
throughout the day.
PMH83
FACTORS THAT INFLUENCE DECISIONS AMONG MBHO NETWORK 
PHYSICIANS TO USE OFFICE-BASED OPIOID TREATMENT OR TO 
INCREASE THE NUMBER OF OPIOID-DEPENDENT PATIENTS THEY 
TREAT: RESULTS FROM THE OBOT ATTITUDE AND INTENTION
PHYSICIAN SURVEY
Ruetsch C, Schoenberger C
Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Although more than 9,000 physicians are certiﬁ ed to prescribe
buprenorphine for opioid dependence (OD), many patients are unsuccessful in access-
ing outpatient OD treatment. Efforts to improve access to ofﬁ ce-based opioid treat-
ment (OBOT) have focused primarily on physician reimbursement or education. To
our knowledge, none have directly queried physicians about factors they view as limi-
tations to treating more OBOT patients. The goal of this study was to understand the
reasons why some providers choose to maintain OBOT patient caseloads below capac-
ity. METHODS: In June 2007, a mail-based, 41-item survey to measure physician 
attitudes, beliefs, and experiences in chronic disease, addiction, and OD was sent to 
a national sample of 621 managed behavioral health care network physicians certiﬁ ed 
to prescribe buprenorphine. Respondents rated the degree to which 11 different sce-
narios independently affect their decision to use OBOT or to increase the number of 
OD patients they treat. Results are reported in terms of physician endorsement (i.e. 
the extent to which each of 11 situations inﬂ uences treatment decisions). The primary 
outcomes measure was the number of OD patients that physicians treat with OBOT. 
RESULTS: The response rate was 47.6% (296 physicians). The ﬁ ve most commonly
endorsed barriers were concerns about coordinating logistics like urine tests (51.3%);
attracting opioid-dependent patients to their practice (50.0%); patients selling 
buprenorphine or taking more than prescribed (48.4%); being available 24/7 for
OBOT patients (48.3%); and ability to send challenging patients to appropriate treat-
ment programs (42.9%). CONCLUSIONS: Managed Care Organizations can improve 
access to OBOT by providing network physicians with logistical guidance and ofﬁ ce
management resources, such as lab testing kits, key opinion leadership, and referrals 
to local treatment centers.
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AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY
MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID
BENEFICIARIES
Esposito D1, Verdier JM2
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Mathematica Policy Research, Inc, 
Washington, DC, USA
OBJECTIVES: To examine whether educational mailings to prescribers of psychotro-
pic medications to Medicaid beneﬁ ciaries improve patient quality of care and reduce 
drug costs. METHODS: Prescribing behavior was compared to pre-intervention
behavior and, where available, to the behavior of prescribers who were not sent mail-
ings. Medicaid pharmacy and eligibility data from April 2003 through September 
2007 were used, as well as data on intervention mailings and deviations from clinical 
guidelines (from which the treatment group was identiﬁ ed). Primary outcome measures 
included clinical deviations, psychotropic claims, and psychotropic costs as a percent-
age of total psychotropic claims or costs. Intervention effects were estimated with
generalized linear regression models controlling for prescriber-level ﬁ xed effects
and a time trend, including sensitivity analyses for various prescriber subgroups. In 
Phase I (March 2004 to November 2005) mailings were sent monthly to qualifying 
prescribers (297; 221 comparison) and in Phase II (March 2006 to January 2007) 
mailings were alternated between prescribers to children (89; 82 comparison) and 
prescribers to adults (145; 354 comparison). RESULTS: Impacts were small and
generally not statistically signiﬁ cant. Prescribing behavior in Phase I and for pre-
scribers to adults in Phase II was not different from existing trends (p  0.10 for 
all outcomes). For prescribers to children, intervention period trends were statistically
different from pre-existing ones for all outcomes; however, they were not different 
when compared with comparison group prescribers. For example, targeted claims 
as a percentage of total claims for treatment group prescribers were slightly lower 
than for the comparison group, but the average difference was less than 1 percentage
point (p  0.12). Effects for all outcomes were not signiﬁ cant until 12 months 
into the intervention. CONCLUSIONS: Psychotropic medications are commonly 
prescribed to Medicaid beneﬁ ciaries. An educational intervention consisting of 
only prescriber mailings is likely not sufﬁ cient to improve quality of care or reduce 
drug costs.
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PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULANTS
FOR ADHD WITH IMMEDIATE-RELEASE STIMULANTS IN CHILDREN
AND ADOLESCENTS
Xiao X1, Damaraju C2, Durkin M2
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Titusville, NJ, USA
OBJECTIVES: To examine patterns of augmentation of extended-release (ER) stimu-
lant regimens with immediate-release (IR) stimulants in a child and adolescent popula-
tion, identify the factors associated with these patterns, and quantify those factors’
effects on likelihood of augmentation. METHODS: Patients with ADHD 6 to 17 years 
of age with prescription claims for at least a 90-day supply from June 2005 to May
2006 for 1 of the following ER stimulants indicated for attention-deﬁ cit/hyperactivity 
disorder (ADHD)—ER dexmethylphenidate (DEX-XR), ER mixed amphetamine salts 
(MAS-XR), or osmotic-release oral system methylphenidate (OROSMPH)—and no 
ADHD medication use in the prior 180 days were selected from a large managed care
database. Descriptive statistics were reported for age, gender, health plan type, region, 
physician specialty, dose level, selected comorbidities, and stimulant cost by augmenta-
tion status and by ER stimulant. Chi-square tests were performed to assess differences 
in categorical variables and Student t tests were used to detect differences for mean 
age. A logistic regression model for predicting positive augmentation status was for-
mulated using backward stepwise regression to evaluate the inclusion of potential
explanatory variables. RESULTS: Of the 5764 eligible patients, 9.5% had IR augmen-
tation with a mean incremental IR drug cost of $22.88 per month. Signiﬁ cant covari-
ates for the logistic model were age (P  0.0171), physician specialty (P  0.0065), 
anxiety diagnosis (P  0.0001), bipolar disorder diagnosis (P  0.0022), and ER 
product (P  0.0001). Likelihood of augmentation was higher with increased age, 
psychiatrist specialty, the presence of diagnoses of anxiety or bipolar disorder, and use 
of DEX-XR. CONCLUSIONS: While this observational study quantiﬁ ed important 
aspects of the augmentation of ER stimulants with IR stimulants from a claims data 
